Measurement of glycated hemoglobin (HbA 1c ) has been the traditional method for assessing glycemic control. However, it does not reflect intra-and interday glycemic excursions that may lead to acute events (such as hypoglycemia) or postprandial hyperglycemia, which have been linked to both microvascular and macrovascular complications. Continuous glucose monitoring (CGM), either from real-time use (rtCGM) or intermittently viewed (iCGM), addresses many of the limitations inherent in HbA 1c testing and self-monitoring of blood glucose. Although both provide the means to move beyond the HbA 1c measurement as the sole marker of glycemic control, standardized metrics for analyzing CGM data are lacking. Moreover, clear criteria for matching people with diabetes to the most appropriate glucose monitoring methodologies, as well as standardized advice about how best to use the new information they provide, have yet to be established. In February 2017, the Advanced Technologies & Treatments for Diabetes (ATTD) Congress convened an international panel of physicians, researchers, and individuals with diabetes who are expert in CGM technologies to address these issues. This article summarizes the ATTD consensus recommendations and represents the current understanding of how CGM results can affect outcomes.
with diabetes who are expert in CGM to address these issues. The purpose of the conference was to provide guidance for clinicians, patients, and researchers in utilizing, interpreting, and reporting CGM data in clinical care and research. The panel was divided into subgroups to review the literature and provide evidence-based recommendations for relevant aspects of CGM utilization and reporting. Primary citations were identified for each topic, assigned a level of evidence (7) (indicated next to the corresponding citation in the text), and verified by the expert panel.
This article summarizes the ATTD consensus recommendations and represents the current state of knowledge on CGM results affecting outcomes. The content represents the consensus of the panel members' comprehensive evaluation of the issues. Supporting evidence is included in the online Supplementary Data identified at the end of each section. target of #6.5% for adults (10) [E] and children (11) [E] . However, all organizations agree that HbA 1c targets should be individualized to each patient. c Although HbA 1c remains the reference marker for assessing glycemic control and predicting the risk of development of long-term complications, it has several limitations: HbA 1c 1) provides only an average of glucose levels over the previous past 2-3 months; 2) does not detect hypoglycemia or hyperglycemia on a daily basis; 3) is an unreliable measure in patients with anemia (12) [B] , hemoglobinopathies (13) [B], or iron deficiency (14) [B] and during pregnancy (15) [B]; 4) does not reflect rapid changes in daily glucose control; and 5) does not provide data as to how to adjust the treatment regimen when HbA 1c levels are elevated. In summary, although HbA 1c has proved extremely valuable in patient management, is a valuable measure of population health, and remains a validated indicator of glycation as a risk factor for complications, it is not as helpful for personalized diabetes management. c The literature suggests that ethnic and racial differences exist in glycation rates (16) (17) (18) [B,C,C], which affects the accuracy of HbA 1c measurements; however, a racial difference was not found in the relationship between mean glucose and fructosamine or glycated albumin levels. This suggests that the racial discordance in glycation rates is specific to red blood cells. Additional discussion of these recommendations and supporting evidence is presented in Appendix 4 of the Supplementary Data.
ASSESSMENT OF GLYCEMIC VARIABILITY Key Findings
c Numerous studies have focused on glycemic variability as an independent risk factor for diabetes complications, particularly cardiovascular disease (60) (61) (62) (63) [C,E,C,C], and on the effects of glycemic variability on cognitive function and quality of life (64) Additional discussion of these recommendations and supporting evidence is presented in Appendix 6 of the Supplementary Data. The key metrics for CGM analysis and reporting are presented in Table 1 . Figure 1 illustrates how these metrics are presented in the AGP.
CONCLUSIONS
CGM is a robust research tool, and continuous glucose data should be recognized by governing bodies as a valuable and meaningful end point to be used in clinical trials of new drugs and devices for diabetes treatment. The identification of hypoglycemia is as important as the measurement of time in range in clinical trials. Quantifying the duration and magnitude of glycemic excursions provides another means of assessing glucose control. The unifying theme of trials investigating the usefulness of CGM technologies is that the device must be worn on a near-daily basis to optimize its benefits.
The expert panel concludes that, in clinical practice, the advanced metrics of assessing continuous glucose data presented here are appropriate as outcome parameters that complement HbA 1c for a wide range of patients with diabetes and should be considered for use to help them improve glycemic control provided that appropriate educational and technical support is available.
